Pfizer Inc. (PFE)
Pfizer And Merck's Earnings Previews: Uncorrelated To Big Tech, And Growth Styles
Both Merck and Pfizer are expected to report their Q2 '24 financial results on Tuesday morning, July 30 '24, before the opening bell. It's time for Pfizer to make hay after the pandemic spike, when the stock jumped from $30 in 2020 to $60 in late '21. Today, Merck is really all about Keytruda and what the pharma giant can squeeze from it, as it awaits further pipeline development.
High Yielding Pfizer Looks Bullish (Technical Analysis)
Pfizer yields 5.57% with a B- dividend safety rating, known for Eliquis and Xeljanz. Technical analysis tools show bullish trends: trading above 30-week EMA, increasing momentum, and improving relative strength. Smart money buying, volume spikes, and breakout from consolidation suggest bullish outlook for Pfizer stock.
Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Will Pfizer Stock Post A Downbeat Q2?
Pfizer (NYSE: PFE) is scheduled to report its Q2 2024 results on Tuesday, July 30. We expect the company to post revenue of $12.95 billion and earnings of $0.44 on a per share and adjusted basis, lower than the consensus estimates.
Pfizer's Q2 Focus: Core Products And New Ventures
Analysts predict Pfizer's Q2 2024 revenue to be around $13 billion. The EPS estimate for Q2 2024 is $0.22, reflecting challenges from decreased COVID-19 product demand. Investors are closely watching the performance of Pfizer's core products, particularly in oncology and vaccines, excluding COVID-19 products.
Seeking Clues to Pfizer (PFE) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics
Get a deeper insight into the potential performance of Pfizer (PFE) for the quarter ended June 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Pfizer (PFE) Gains 7.3% in 2024 on its Weigh-Loss Drug Pipeline
Shares of Pfizer (PFE) are up 7.3% in 2024, based on its weight-loss drug program. The stock must be watched for further developments.
Beware, Wegovy -- Pfizer Is Working on a Competitor
Pfizer's weight loss candidate is moving closer to pivotal studies. This product had encouraging results in phase 2 studies.
UK regulator authorises Pfizer-BioNTech shot for JN.1 COVID variant
Britain's health regulator said on Wednesday it has authorised Pfizer and BioNTech's updated COVID-19 vaccine that targets the JN.1 subvariant of the coronavirus for use in infants, children and adults.
Sangamo Stock Spikes As Pfizer Partnership Meets Goal In Late-Stage Study
Sangamo Therapeutics Inc SGMO, which developed a treatment in collaboration with Pfizer Inc PFE, received a boost to its stock price after struggling with liquidity issues.
Pfizer (PFE) Q2 Earnings Coming Up: What Should Investors Do?
Pfizer ( PFE) will report its second-quarter 2024 earnings on Jul 30, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at $13.22 billion and 45 cents per share, respectively.
This Promising Weight Loss Drug Candidate Could Be a Huge Growth Catalyst for Pfizer
Pfizer is developing danuglipron -- a once-daily weight loss drug. In studies of a twice-daily version, some trial participants lost more than 10% of their body weight.
